The Impact of Omega-3 Supplementation on Gene Expression in Type 2 Diabetics
The Impact of Omega-3 Supplementation on Acylation Stimulating Protein(ASP), Retinol-binding Protein 4 (RBP4) and Lipocalin-2 (LCN2) Gene Expression of ASP Receptor (C5L2) in WBC of Patient With Diabetes Type 2
Sponsor: Tehran University of Medical Sciences
A PHASE4 clinical study on Type 2 Diabetes, this trial is ongoing. The trial is conducted by Tehran University of Medical Sciences and has accumulated 7 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE4
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status PHASE4
Status: Enrolling By Invitation → Unknown Status
-
Jan 2017 — Feb 2017 [monthly]
Enrolling By Invitation PHASE4
First recorded
Dec 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Tehran University of Medical Sciences
For direct contact, visit the study record on ClinicalTrials.gov .